Covid-19 vaccines and the long road ahead to normalcy

While the exuberance about vaccines is understandable, a full return to pre-pandemic conditions will require much more work to be done, including establishing national and global frameworks and infrastructure for recording and verifying who has received an accredited vaccine.

Dr Steve Brandwene receiving a Pfizer-BioNtech Covid-19 vaccine at the Research Centers of America in Hollywood, on Dec 18, 2020. PHOTO: AFP
New: Gift this subscriber-only story to your friends and family

In the past four weeks, the world greeted the continual positive findings from several late-stage Covid-19 vaccine trials with loud cheers. Global stock markets rallied, and the surge in share prices of aviation and tourism counters revealed the widespread optimism of the world about a return to pre-Covid-19 normalcy.

This enthusiasm is reinforced whenever governments worldwide announce their plans to procure and deliver the vaccines, regardless of the important caveat to prioritise limited vaccine doses for front-line workers and high-risk groups before mass distribution to the rest of the population is possible.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.